At a glance
ClinicalIndex Comparison Record- ✓African American or Caucasian with diagnosed CVD (prior MI, revascularization, ischemic heart disease, stroke) or type 2 diabetes not on therapy
- ✓Currently receiving medical care at Johns Hopkins University
- ✓LDL cholesterol ≥100 mg/dL on or off lipid-lowering therapy, or no LDL-C recorded in past 12 months
- ✓Blood pressure >140/90 mmHg (or >130/80 if diabetic/renal insufficiency), or no BP recorded in past 12 months
- ✕Life-threatening non-cardiac comorbidity with life expectancy <5 years
- ✕Serious physician-recorded psychiatric disorder interfering with study participation
- ✕Significant neurological impairment interfering with study participation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reducing Total Cardiovascular Risk in an Urban Community
In Brief
A Phase 4 clinical trial evaluating Lifestyle Changes, Antiplatelet Agents, and 2 other interventions for Cardiovascular Diseases and 6 related conditions. Completed, enrolled 525 participants across 1 site.
Detailed Summary
PLEASE NOTE: THIS STUDY IS ONLY ENROLLING PATIENTS CURRENTLY BEING TREATED AT BELAIR-EDISON FAMILY HEALTH CENTER. The purpose of this study is to compare the clinical effectiveness and cost effectiveness of two cardiovascular risk reduction programs - a comprehensive intensive (Cl) intervention with a less intensive (LI) intervention - in African American, and white low-income patients with known excessive cardiovascular disease risk.
Study Details
Timeline
Interventions
Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
Aspirin 81 mg q day
Oral medication
Oral medications, received 1-2 times per day